Tiziana Life Sciences (TLSA) Common Equity (2017 - 2025)
Tiziana Life Sciences (TLSA) posted quarterly Common Equity of $52000.0 for Q4 2025, down 98.68% year-over-year from $3.9 million in Q4 2024, and up 100.92% quarter-over-quarter from -$5.6 million in Q2 2025.
Tiziana Life Sciences (TLSA) Common Equity (2017 - 2025) Analysis & Trends
Tiziana Life Sciences' Common Equity history runs 9 years deep, the most recent figure standing at $52000.0 for Q4 2025.
- In Q4 2025, Common Equity fell 98.68% year-over-year to $52000.0; the TTM figure through Dec 2025 stood at $52000.0 (down 98.68% YoY), while the FY2025 annual figure was $52000.0, up 100.44% from the prior year.
- Common Equity for Q4 2025 stood at $52000.0, up from -$5.6 million in the prior quarter.
- The five-year high for Common Equity was $41.3 million in Q4 2021, with the low at -$17.0 million in Q2 2021.
- The 5-year median for Common Equity is -$2.2 million (2022), against an average of $3.0 million.
- Peak annual rise in Common Equity reached 253.64% in 2021, while the deepest fall reached 248.34% in 2021.
- Tiziana Life Sciences' Common Equity stood at $41.3 million in 2021, then slumped by 52.59% to $19.6 million in 2022, then plunged by 71.71% to $5.5 million in 2023, then retreated by 28.9% to $3.9 million in 2024, then tumbled by 98.68% to $52000.0 in 2025.
- Business Quant data shows TLSA's Common Equity at $52000.0 in Q4 2025, -$5.6 million in Q2 2025, and $3.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Tiziana Life Sciences | 133.66 Mn | 129.65 Mn | - | 52,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 52,000.00 |
| Jun 30, 2025 | -5.63 Mn |
| Dec 31, 2024 | 3.94 Mn |
| Jun 30, 2024 | -4.65 Mn |
| Dec 31, 2023 | 5.54 Mn |
| Jun 30, 2023 | -8.62 Mn |
| Dec 31, 2022 | 19.57 Mn |
| Jun 30, 2022 | -4.51 Mn |
| Dec 31, 2021 | 41.28 Mn |
| Jun 30, 2021 | -17.02 Mn |
| Dec 31, 2020 | -26.87 Mn |
| Jun 30, 2020 | -4.88 Mn |
| Dec 31, 2019 | -9.39 Mn |
| Jun 30, 2019 | -4.66 Mn |
| Dec 31, 2018 | 528,861.33 |
| Jun 30, 2018 | -5.26 Mn |
| Dec 31, 2017 | -8.99 Mn |